Mastocytosis

Dermatologic Clinics

Volumn 19, Issue 4, 2001, Pages 679-696

  Tharp, Michael D ^a   Longley Jr, B Jack ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALPHA2B INTERFERON; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; CETIRIZINE; CIMETIDINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN A; DIMETHYLTUBOCURARINE CHLORIDE; DIPHENHYDRAMINE; DOXEPIN; ETOMIDATE; FAMOTIDINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; ISOFLURANE; LORATADINE; NIZATIDINE; PREDNISONE; RANITIDINE; THIOPENTAL; TRIAMCINOLONE ACETONIDE; TRICYCLIC ANTIDEPRESSANT AGENT; TUBOCURARINE CHLORIDE;

BLOOD ANALYSIS; CELL INFILTRATION; CELL STIMULATION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; MAST CELL; MASTOCYTOSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PUVA; RADIODIAGNOSIS; REVIEW; SERODIAGNOSIS; TREATMENT PLANNING; URINALYSIS;

EID: 0034760233     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70308-9     Document Type: Article

References (173)

1. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms
2. Skeletal mastocytosis
3. Solitary mastocytoma in an adult
4. Systemic mastocytosis: CT and US features of abdominal manifestations
5. Heparin-induced osteopenia: An appraisal
6. Systemic mastocytosis and other mast cell neoplasms
7. Telangectasis macularis eruptive perstans: Report of an early stage in a child
8. Mast cell cholangiopathy: Another cause of sclerosing cholangitis
9. Treatment of urticaria pigmentosa with corticosteroids
10. Histamine
11. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli
12. c-Kit and c-Kit mutation in mastocytosis and other hematological diseases
13. Anesthesia in a patient with malignant systemic mastocytosis using a total intravenous anesthetic technique
14. Human mast cell cytokines
15. Heterogeneity of human mast cells based on cytokine content
16. Response of severe systemic mastocytosis to interferon-alpha
17. Identification of activation c-kit mutations in adult but not in childhood-onset indolent mastocytosis: A possible explanation for divergent clinical behavior
18. The natural course of urticaria pigmentosa
19. Induction of human cutaneous mast cell degranulation by opiates and endogenous peptides: Evidence for opiate and non-opiate receptor participation
20. Dissociated human foreskin mast cells degranulate in response to anti-IgE and substance P
21. 2 receptors in the human peripheral circulation
22. Tripe palms associated with systemic mastocytosis: The role of transforming growth factor-α and efficacy of interferon-alpha
23. PUVA treatment of urticaria pigmentosa
24. Adenosine triphosphate evoked vascular changes in human skin: Mechanisms of action
25. Ultrastructural analysis of human T and TC mast cells identified by immuno-electron microscopy
26. Human MCTC type of mast cell granule: The uncommon occurrence of discrete scrolls associated with focal absence of chymase
27. Interferon treatment of patients with chronic urticaria and mastocytosis
28. Stem cell factor is localized in, released from, and cleaved by human mast cells
29. Massive histamine release in a patient with systemic mastocytosis
30. Mast cell population density, blood vessel density and histamine content in normal human skin
31. Beiträge zur Kenntnis der Anilinfarbungen und ihrer Verwendurg in der Mikroskopischen Technik
32. Treatment of telangiectasia macularis eruptive perstans with the 585 nm flashlam-pumped dye laser
33. Urticaria pigmentosa-Report of a case with autopsy
34. Interferon treatment of human malignancies-a short review
35. Systemic mastocytosis associated with generalized osteopenia
36. Histaminuria from histamine-rich foods
37. The c-kit ligand: A cell surface molecule altered in steel mutant fibroblasts
38. Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis
39. Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis
40. Urticaria pigmentosa and acute lymphoblastic leukemia
41. Y: c-Kit kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas
42. Identification of mutation in the coding sequence of the protooncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product
43. New concepts about the mast cell
44. Human osteoclasts and preosteoclast cells (FLG 29.1) express functional c-kit receptors and interact with osteoblast and stromal cells via membrane-bound stem cell factor
45. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene
46. Telangiectasia macularis eruptive perstans
47. Short-and longterm effectiveness of oral and bath UPVA therapy in urticaria pigmentosa and systemic mastocytosis
48. Human mast cell carboxypeptidase. Purification and characterization
49. Identification and partial characterization of human mast cell carboxypeptidase
50. Urinary excretion of histamine, methyl histamine and methyl imidiazole acetic acids in man under standardized dietary conditions
51. No relationship between histamine release measured as metabolite excretion in the urine, and serum levels of mast cell specific tryptase in mastocytosis
52. Studies on histamine metabolism in mastocytosis
53. Increased urinary methyl imidiazole acetic acid (MeImAA) as an indicator of systemic mastocytosis
54. Decreased urinary histamine after successful PUVA treatment of urticaria pigmentosa
55. Pseudoxanthomatous mastocytosis
56. Pigmentation and proliferation of human melanocytes and the effect of melanocyte-stimulating hormone and ultraviolet
57. Expression of stem cell factor in cutaneous mastocytosis
58. MRI characteristics of systemic mastocytosis of the lumbosacral spine
59. Systemic mastocytosis-a case with interferon-α and radiotherapy
60. An electron microscopic study of the degranulation of mast cell granules in urticaria pigmentosa
61. Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis
62. Mastocytosis of the axial skeleton presenting as an epidural mass lesion
63. Systemic mastocytosis: Retrospective review of a decade's clinical experience at the Brigham and Women's Hospital
64. Cromolyn sodium in the management of systemic mastocytosis
65. Diagnostic criteria and classification of mastocytosis: A consensus proposal
66. Sudden intraoperative hypotension in a patient with asymptomatic urticaria pigmentosa
67. Human mast cell carboxypeptidase: Selective localization of MCTC cells
68. Two types of human mast cells that have distinct neutral protease compositions
69. Identification of gamma-E antibodies as a carrier of reaginic activity
70. Radiotherapy of refractory bone pain due to neutral protease compositions
71. The potential clinical utility of serum α-protryptase levels
72. Diagnosis of mastocytosis subsets using a morphometric point counting technique
73. Quantification of cutaneous mast cells using morphometric point counting and a conjugated avidin stain
74. Pediatric mastocytosis
75. Hematopathology of the bone marrow in pediatric cutaneous mastocytosis
76. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites
77. Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34 + pluripotent progenitor cells
78. Demonstration of the origin of human mast cells from CD34 + bone marrow progenitor cells
79. d genotype
80. Response to interferon alpha- 2b in a patient with systemic mastocytosis
81. Response of cutaneous mast cells to PUVA in patients with urticaria pigmentosa: Histomorphometric, ultrastructural, and biochemical investigations
82. Long-term follow-up of indolent mastocytosis in adults
83. Heterogeneity of mast cells in mastocytosis and inhibitory effect of ketotifen and ranitidine on indolent systemic mastocytosis
84. Response to cyclosporin and low dose methylprednisone in aggressive systemic mastocytosis
85. Cell biology of mast cells and basophils
86. Steel factor and c-kit proto-oncogene: Genetic lessons in signal transduction
87. Interleukin-6 messenger RNA expression and interleukin-6 protein secretion in cells isolated from normal human bone: Regulation by interleukin-1
88. Trisomies 9 and 8 detected by fluorescence in situ hybridization in patients with systemic mastocytosis
89. A proposed classification system of mastocytosis incorporating molecular genetics
90. Activating and dominant inactivating c-kit catalytic domain mutations in distinct forms of human mastocytosis
91. Altered metabolism of mast cell growth factor (c-kit ligand) in cutaneous mastocytosis
92. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm
93. Chymase cleavage of stem cell factor yields a bioactive, soluble product
94. Chronically KIT-stimulated clonally-derived human mast cells show heterogeneity in different tissue microenvironments
95. Mastocytosis with skeletal and gastrointestinal involvement in infancy. Two case reports and a review of the literature
96. Systemic mast cell disease associated with the hypereosinophilic syndrome
97. Histomorphometric study of mast cells in normal bone, osteoporosis, and mastocytosis using a new stain
98. Lymphadenopathic mastocytosis with eosinophilia
99. Systemic mastocytosis with the diffuse crocodile-like pachydermic skin, pedunculated pseudofibromas and comedones
100. Classification and diagnosis of mastocytosis: Current status
101. The liver, spleen, and lymph nodes in mastocytosis
102. Hepatic involvement in mastocytosis: Clinicopathologic correlations in 41 Cases
103. Mast cell population in skin
104. Expression of high-affinity binding of human immunoglobulin E by transfected cells
105. The role of the mast cell in clinical gastrointestinal disease with special reference to systemic mastocytosis
106. Human mast cells produce IL- 8
107. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D 2
108. Histamine release by narcotics and muscle relaxants in humans
109. Bullous mastocytosis: A fatal outcome
110. c-Kit mutation in a population of patients with mastocytosis
111. Identification of a point mutation in the catalytic domain of the protooncogene c-KIT in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
112. Rare forms of urticaria
113. IgE-dependent expression of mRNA for IL-4 and IL- 5 in human being mast cells
114. Bullous mastocytosis
115. Fine structure of the mast cell with special reference to human cells
116. Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon
117. Hematologic aspects of mastocytosis: I: Bone marrow pathology in adult and pediatric systemic mast cell disease
118. Systemic mastocytosis associated with chronic myelomonocytic leukemia: Clinical features and response to interferonalpha theraphy
119. A new c-kit mutation in a case of aggressive mast cell disease
120. The roentgen manifestations of urticaria pigmentosa (mastocytosis)
121. Tricyclic antidepressants and H 1 receptors
122. Increased production of prostaglandin D 2 in patients with systemic mastocytosis
123. Urticaria pigmentosa in identical twins
124. Mixed organic brain syndrome as a manifestation of systemic mastocytosis
125. Patterns of skeletal scintigraphy and their relationship to plasma and urinary histamine levels in systemic mastocytosis
126. The effect of histamine on the growth of cultured fibroblasts isolated from normal and keloid tissue
127. Identification of a cathepsin G-like proteinase in the MCTC type of human mast cell
128. Characterization of inflammatory mediator release from purified human lung mast cells
129. Severe shock during upper GI endoscopy in a patients with systemic mastocytosis
130. Tryptase from human mast cells: Biochemistry, biology and clinical utility
131. The α form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis
132. Endoscopic findings in systemic mastocytosis
133. Hazards in operative management of patients with systemic mastocytosis
134. A clinical genetic evaluation
135. Uniovular twins discordant for cutaneous mastocytosis
136. Genetic aspects of urticaria pigmentosa
137. 1-receptor antagonists: Clinical pharmacology
138. Mastocytosis in childhood
139. Immunological repertoire of the dermal microvascular unit
140. The skin in mastocytosis
141. Oral disodium cromoglycate in the treatment of systemic mastocytosis
142. Interleukin I releases histamine from human basophils and mast cells in vitro
143. Histamine liberation by codeine and polymyxin B in urticaria pigmentosa
144. The interaction between mast cells and endothelial cells
145. The mast cell and its mediators
146. In vitro functional reactivities of cutaneous mast cells from patients with mastocytosis
147. Ultrastructural morphometric analysis of human mast cells from normal skin and pathologic cutaneous lesions
148. Cutaneous mast cell stimulation by adenosine-triphosphate (ATP)
149. Urticaria pigmentosa-Solitary lesion in an adult
150. Pathology of the lymph node and spleen in systemic mast cell disease
151. Systemic mast cell disease
152. Mast cell leukemia: Report of a case and review of the literature
153. Intervention with epinephrine in hypotension associated with mastocytosis
154. Anatomie und Pathogenese dur urticaria simples und pigmentosa
155. Recent advances in mastocytosis research
156. Value of urinary N-methylhistamine measurements in childhood mastocytosis
157. Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa
158. Updates on cells and cytokines: The protooncogene c-kit and c-kit ligand in human disease
159. Human dermal mast cells contain and release tumor necrosis factor-α which induces endothelial leukocyte adhesion molecule-I
160. Heterogeneity of human Fc epsilon RI-bearing cells
161. Mast cell leukemia presenting as urticaria pigmentosa
162. Systemic mast cell disease: A clinical and hematopathologic study of 26 cases
163. Evidence for morphologic diversity of human mast cells. An ultrastructural study of mast cells from multiple body sites
164. Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content
165. Ultrastructural and immunohistochemical characterization of normal mast cells at multiple body sites
166. Electron microscopical evidence for a direct contact between nerve fibres and mast cells
167. Neutrophils and mast cells. Comparison of neutrophil-derived histamine-releasing activity with other histamine-releasing factors
168. Diffuse cutaneous mastocytosis with multiple cutaneous mastocytoma
169. Treatment of three patients with systemic mastocytosis with interferon alpha- 2b
170. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis
171. Hepatic involvement in systemic mast cell disease